Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.
Bolsewig K, Willemse EAJ, Sánchez-Juan P, Rábano A, Martínez M, Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Koel-Simmelink M, Hussainali Z, Ruiters DN, Gaetani L, Toja A, Fortea J, Pijnenburg Y, Lemstra AW, van der Flier WM, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, Teunissen CE, Del Campo Milán M.
Bolsewig K, et al. Among authors: martinez m.
Nat Commun. 2025 Jan 29;16(1):1139. doi: 10.1038/s41467-025-56293-z.
Nat Commun. 2025.
PMID: 39881147
Free PMC article.